World's Best Scientists 2026 revealed!
Michael R. Zalutsky

Michael R. Zalutsky

D-Index & Metrics

Medicine

D-Index
84
Citations
21197
World Ranking
15291
National Ranking
7715

Overview

Michael R. Zalutsky is affiliated with Duke University in the United States and has a research profile centered primarily in the field of Medicine. Their work covers multiple subfields, including Radiology, Nuclear Medicine and Imaging, Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, and Genetics.

The main topics of their research include:

  • Radiopharmaceutical Chemistry and Applications
  • Monoclonal and Polyclonal Antibodies Research
  • HER2/EGFR in Cancer Research
  • Medical Imaging Techniques and Applications
  • Medical Imaging and Pathology Studies
  • Prostate Cancer Treatment and Research
  • Peptidase Inhibition and Analysis

Their publications have appeared frequently in the following venues:

  • Nuclear Medicine and Biology
  • Journal of Nuclear Medicine
  • Frontiers in Pharmacology
  • Nature Biomedical Engineering
  • Scientific Reports

Some of the recent papers by Michael R. Zalutsky include:

  • Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy, 2020, Frontiers in Pharmacology
  • Production, purification and availability of 211At: Near term steps towards global access, 2021, Nuclear Medicine and Biology
  • An Improved 211At-Labeled Agent for PSMA-Targeted α-Therapy, 2021, Journal of Nuclear Medicine
  • Brachytherapy via a depot of biopolymer-bound 131I synergizes with nanoparticle paclitaxel in therapy-resistant pancreatic tumours, 2022, Nature Biomedical Engineering
  • Synthesis and preliminary evaluation of 211At-labeled inhibitors of prostate-specific membrane antigen for targeted alpha particle therapy of prostate cancer, 2021, Nuclear Medicine and Biology

Frequent collaborators in their research include:

  • Ganesan Vaidyanathan
  • Yutian Feng
  • Zhengyuan Zhou
  • Rebecca Meshaw
  • Darryl McDougald

Best Publications

  • Monoclonal Antibodies against EGFRvIII Are Tumor Specific and React with Breast and Lung Carcinomas and Malignant Gliomas

    Carol J. Wikstrand;Laura P. Hale;Surinder K. Batra;M. Leslie Hill

  • Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma.

    Peter A. Humphrey;Albert J. Wong;Bert Vogelstein;Michael R. Zalutsky

  • Clinical Experience with α-Particle–Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6

    Michael R. Zalutsky;David A. Reardon;Gamal Akabani;R. Edward Coleman

  • Pinhole collimation for ultra-high-resolution, small-field-of-view SPECT

    R J Jaszczak;Jianying Li;Huili Wang;M R Zalutsky

  • Phase II Trial of Murine 131I-Labeled Antitenascin Monoclonal Antibody 81C6 Administered Into Surgically Created Resection Cavities of Patients With Newly Diagnosed Malignant Gliomas

    David A. Reardon;Gamal Akabani;R. Edward Coleman;Allan H. Friedman

  • Progress Report of a Phase I Study of the Intracerebral Microinfusion of a Recombinant Chimeric Protein Composed of Transforming Growth Factor (TGF)-α and a Mutated form of the Pseudomonas Exotoxin Termed PE-38 (TP-38) for the Treatment of Malignant Brain Tumors

    John H. Sampson;Gamal Akabani;Gary E. Archer;Darell D. Bigner

  • Targeting a Genetically Engineered Elastin-like Polypeptide to Solid Tumors by Local Hyperthermia

    Dan E. Meyer;Garheng A. Kong;Mark W. Dewhirst;Michael R. Zalutsky

  • A Plasmonic Gold Nanostar Theranostic Probe for In Vivo Tumor Imaging and Photothermal Therapy

    Yang Liu;Jeffrey R Ashton;Everett J Moding;Hsiangkuo Yuan

  • Radiolocalization of human mammary tumors in athymic mice by a monoclonal antibody.

    David Colcher;Michael Zalutsky;William Kaplan;Donald Kufe

  • Salvage Radioimmunotherapy With Murine Iodine-131–Labeled Antitenascin Monoclonal Antibody 81C6 for Patients With Recurrent Primary and Metastatic Malignant Brain Tumors: Phase II Study Results

    David A. Reardon;Gamal Akabani;R. Edward Coleman;Allan H. Friedman

  • Astatine-211-Labeled Radiotherapeutics An Emerging Approach to Targeted Alpha-Particle Radiotherapy

    Michael Zalutsky;Ganesan Vaidyanathan

  • The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target

    C J Wikstrand;C J Reist;G E Archer;M R Zalutsky

  • A method for the radiohalogenation of proteins resulting in decreased thyroid uptake of radioiodine.

    Michael R. Zalutsky;Acharan S. Narula

  • Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.

    D D Bigner;M T Brown;A H Friedman;R E Coleman

  • A thermally responsive biopolymer for intra-articular drug delivery.

    Helawe Betre;Wenge Liu;Michael R. Zalutsky;Ashutosh Chilkoti

  • Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors

    John H. Sampson;Gamal Akabani;Gerald E. Archer;Mitchel S. Berger

  • Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity.

    Michael R. Zalutsky;Pradeep K. Garg;Henry S. Friedman;Darell D. Bigner

  • Phase I Trial Results of Iodine-131–Labeled Antitenascin Monoclonal Antibody 81C6 Treatment of Patients With Newly Diagnosed Malignant Gliomas

    Ilkcan Cokgor;Gamal Akabani;Chien-Tsun Kuan;Henry S. Friedman

  • Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and auger electron-emitting radionuclides

    Marie Boyd;Susan C Ross;Jennifer Dorrens;Natasha E Fullerton

  • Molecular Imaging of Hypoxia

    Satish K. Chitneni;Gregory M. Palmer;Michael R. Zalutsky;Mark W. Dewhirst

Frequent Co-Authors

Darell D. Bigner
Darell D. Bigner Duke University
Henry S. Friedman
Henry S. Friedman Duke University
Roger E. McLendon
Roger E. McLendon Duke University
Allan H. Friedman
Allan H. Friedman Duke University
Ashutosh Chilkoti
Ashutosh Chilkoti Duke University
Mark W. Dewhirst
Mark W. Dewhirst Duke University
David A. Reardon
David A. Reardon Harvard University
R. Edward Coleman
R. Edward Coleman Duke University
James E. Herndon
James E. Herndon Duke University
Robert C. Bast
Robert C. Bast The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring allied health and related online degrees can open flexible pathways for those interested in medicine or healthcare. For those without a nursing background, msn direct entry programs online let you fast-track into advanced nursing roles without prior RN experience.

If you’re aiming for a straightforward entry to nursing, direct admit nursing programs often feature simplified admission criteria, helping you start your career sooner. Some programs even allow you to bypass entrance exams like the TEAS or HESI—find out more about whether do i need to take the teas test for lpn entry at select schools.

Healthcare extends beyond patient care—administrative roles are also in demand. Pursuing education at medical billing and coding online schools can prepare you for vital support careers, often with flexible, remote learning options.

Each of these pathways can provide rewarding healthcare careers while accommodating diverse lifestyles or educational backgrounds.

Best Scientists Citing Michael R. Zalutsky

Trending Scientists